News

Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day
This was the stock's fourth consecutive day of gains.
Regeneron (REGN) Scores FDA Approval, JP Morgan Reaffirms $800 Price Target
On the other side, on July 7, JP Morgan analyst Chris Schott reiterated a Buy rating on Regeneron, while maintaining his $800 ...
STAT2d
How Regeneron, maker of a best-selling eye drug, is using patent tactics to try to thwart competition
A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...
Assessing Regeneron Pharmaceuticals: Insights From 26 Financial Analysts
Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.
GEN - Genetic Engineering and Biotechnology News4d
End-to-End: Fujifilm Rebrands Life Sciences Companies, Positioning Itself as Drug Development Cycle Leader
Fujifilm’s Life Sciences Group is renaming two of its companies, in a rebranding intended to position parent company Fujifilm ...